Replies to post #409339 on NorthWest Biotherapeutics Inc (NWBO)

[danielboog2]

Stand alone....TLD could have been PR'd nearly a year ago. I don't think the Journal is the "1000# Gorilla", I believe the BLA and all the parts have overwhelmed NWBO's manpower and expertise and needs their total attention.

I'm not being critical. The data is enormously complex. Defining a path and executing requires an almost genius plan. So many pieces for a BLA. All else is subordinate....or at least until the BLA has finalized for application.

[danielboog2]

That too would be sensible to PR the TLD before BLA....that would create more credibility to the BLA publicity. As I have noticed, the FDA needs to be the lead entity to evaluate the Trial Data and not be subordinate to the Scientific Data Published in a Journal.

Just some thoughts.